A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia

Stopped early · Not applicable · Has a placebo group

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia.The primary aim of this pilot trial is to provide an effect size estimate for the efficacy of curcumin in improving cognitive functioning in schizophrenia. Secondary goals are to determine the effect of curcumin over time on negative and positive symptoms, in association with inflammatory markers.

Key facts

Study ID
NCT02476708
Run by
Yale University
People needed
12
Starts
2016-02-11
Expected to finish
2017-08-24
Last updated by the study team
2018-01-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.